For research use only. Not for therapeutic Use.
Verteporfin(CAT: I013885) is a medication used in photodynamic therapy (PDT) for the treatment of certain eye conditions. It is a photosensitizing agent that is activated by light to produce reactive oxygen species, leading to localized tissue damage. In ophthalmology, verteporfin is primarily employed in the treatment of age-related macular degeneration (AMD), specifically the predominantly classic subtype. It is administered intravenously and selectively accumulates in abnormal blood vessels in the eye. Upon activation by laser light, it causes occlusion and destruction of these vessels, helping to slow down the progression of AMD and preserve vision.
| Catalog Number | I013885 |
| CAS Number | 129497-78-5 |
| Molecular Formula | C₄₁H₄₂N₄O₈ |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | DMSO: 5.6 mg/mL |
| IUPAC Name | 3-[(23R,24S)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid |
| InChI | InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1 |
| InChIKey | NJLRKAMQPVVOIU-IDLGWYNRSA-N |
| SMILES | CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C |
